Cambium Bio Ltd (CMB) - Net Assets

Latest as of June 2025: AU$1.84 Million AUD ≈ $1.30 Million USD

Based on the latest financial reports, Cambium Bio Ltd (CMB) has net assets worth AU$1.84 Million AUD (≈ $1.30 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$3.30 Million ≈ $2.33 Million USD) and total liabilities (AU$1.46 Million ≈ $1.03 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Cambium Bio Ltd (CMB) asset resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	AU$1.84 Million
% of Total Assets	55.71%
Annual Growth Rate	-15.13%
5-Year Change	-55.72%
10-Year Change	-61.63%
Growth Volatility	145.79

Cambium Bio Ltd - Net Assets Trend (1999–2025)

This chart illustrates how Cambium Bio Ltd's net assets have evolved over time, based on quarterly financial data. Also explore CMB total assets for the complete picture of this company's asset base.

Annual Net Assets for Cambium Bio Ltd (1999–2025)

The table below shows the annual net assets of Cambium Bio Ltd from 1999 to 2025. For live valuation and market cap data, see Cambium Bio Ltd stock valuation.

Year	Net Assets	Change
2025-06-30	AU$1.84 Million ≈ $1.30 Million	-33.88%
2024-06-30	AU$2.78 Million ≈ $1.96 Million	+242.33%
2023-06-30	AU$-1.95 Million ≈ $-1.38 Million	-281.49%
2022-06-30	AU$1.07 Million ≈ $760.48K	-74.07%
2021-06-30	AU$4.15 Million ≈ $2.93 Million	+278.91%
2020-06-30	AU$1.09 Million ≈ $774.10K	+117.13%
2019-06-30	AU$-6.39 Million ≈ $-4.52 Million	-318.58%
2018-06-30	AU$2.92 Million ≈ $2.07 Million	-63.93%
2017-06-30	AU$8.10 Million ≈ $5.73 Million	+69.29%
2016-06-30	AU$4.78 Million ≈ $3.39 Million	-42.16%
2015-06-30	AU$8.27 Million ≈ $5.85 Million	-0.43%
2014-06-30	AU$8.31 Million ≈ $5.88 Million	+389.60%
2013-06-30	AU$-2.87 Million ≈ $-2.03 Million	-247.22%
2012-06-30	AU$1.95 Million ≈ $1.38 Million	-40.72%
2011-06-30	AU$3.29 Million ≈ $2.33 Million	+139.78%
2010-06-30	AU$1.37 Million ≈ $970.07K	-96.62%
2002-06-30	AU$40.54 Million ≈ $28.68 Million	-79.34%
2001-06-30	AU$196.21 Million ≈ $138.83 Million	+21.80%
2000-06-30	AU$161.09 Million ≈ $113.98 Million	+23.39%
1999-06-30	AU$130.56 Million ≈ $92.38 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Cambium Bio Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 215.5% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component	Amount	Percentage
Common Stock	AU$46.54 Million	2535.25%
Other Comprehensive Income	AU$1.89 Million	102.74%
Total Equity	AU$1.84 Million	100.00%

Cambium Bio Ltd Competitors by Market Cap

The table below lists competitors of Cambium Bio Ltd ranked by their market capitalization.

Company	Market Cap
TAIZHOU WATER GRP. H YC 1 F:GX5	$6.66 Million
Zimtu Capital Corp V:ZC	$6.66 Million
Largo SAS PA:ALLGO	$6.67 Million
Jayud Global Logistics Limited Class A Ordinary Shares NASDAQ:JYD	$6.67 Million
Griffin Mining LSE:GFM	$6.66 Million
CEA Industries Inc NASDAQ:CEAD	$6.66 Million
YLI Holdings Bhd KLSE:7014	$6.66 Million
Slam Exploration Ltd. V:SXL	$6.66 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Cambium Bio Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 2,776,331 to 1,835,748, a change of -940,583 (-33.9%).
Net loss of 3,844,251 reduced equity.
New share issuances of 2,880,707 increased equity.
Other comprehensive income decreased equity by 4,961.
Other factors increased equity by 27,922.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	AU$-3.84 Million	-209.41%
Share Issuances	AU$2.88 Million	+156.92%
Other Comprehensive Income	AU$-4.96K	-0.27%
Other Changes	AU$27.92K	+1.52%
Total Change	AU$-	-33.88%

Book Value vs Market Value Analysis

This analysis compares Cambium Bio Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 4.08x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 0.61x to 4.08x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1999-06-30	AU$0.67	AU$0.41	x
2000-06-30	AU$0.82	AU$0.41	x
2001-06-30	AU$0.96	AU$0.41	x
2002-06-30	AU$0.21	AU$0.41	x
2010-06-30	AU$0.01	AU$0.41	x
2011-06-30	AU$1.69	AU$0.41	x
2012-06-30	AU$1.00	AU$0.41	x
2013-06-30	AU$-1.48	AU$0.41	x
2014-06-30	AU$4.88	AU$0.41	x
2015-06-30	AU$3.95	AU$0.41	x
2016-06-30	AU$2.24	AU$0.41	x
2017-06-30	AU$3.79	AU$0.41	x
2018-06-30	AU$1.37	AU$0.41	x
2019-06-30	AU$-2.99	AU$0.41	x
2020-06-30	AU$0.41	AU$0.41	x
2021-06-30	AU$0.01	AU$0.41	x
2022-06-30	AU$0.35	AU$0.41	x
2023-06-30	AU$-0.59	AU$0.41	x
2024-06-30	AU$0.67	AU$0.41	x
2025-06-30	AU$0.10	AU$0.41	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Cambium Bio Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -209.41%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -573.72%
• Asset Turnover: 0.20x
• Equity Multiplier: 1.79x
Recent ROE (-209.41%) is below the historical average (-77.79%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1999	11.78%	9.49%	0.56x	2.21x	AU$2.28 Million
2000	17.64%	14.05%	0.67x	1.86x	AU$11.87 Million
2001	11.14%	9.86%	0.63x	1.78x	AU$2.09 Million
2002	-209.91%	-41.24%	4.02x	1.27x	AU$-87.16 Million
2011	-52.40%	-219.21%	0.19x	1.28x	AU$-2.05 Million
2012	-167.34%	-274.90%	0.36x	1.69x	AU$-3.46 Million
2013	0.00%	-302.22%	0.43x	0.00x	AU$-4.91 Million
2014	-90.55%	-395.53%	0.19x	1.23x	AU$-8.35 Million
2015	-79.86%	-362.93%	0.19x	1.16x	AU$-7.43 Million
2016	-74.69%	-205.93%	0.29x	1.24x	AU$-4.05 Million
2017	40.38%	32.73%	1.09x	1.13x	AU$2.46 Million
2018	-177.45%	-901.03%	0.12x	1.71x	AU$-5.48 Million
2019	0.00%	-24024.40%	0.01x	0.00x	AU$-5.39 Million
2020	-81.72%	-53.75%	0.35x	4.38x	AU$-1.00 Million
2021	66.56%	39.04%	0.83x	2.05x	AU$2.34 Million
2022	-400.98%	0.00%	0.00x	2.38x	AU$-4.42 Million
2023	0.00%	0.00%	0.00x	0.00x	AU$-3.20 Million
2024	-81.25%	-313736.44%	0.00x	2.03x	AU$-2.53 Million
2025	-209.41%	-573.72%	0.20x	1.79x	AU$-4.03 Million

Industry Comparison

This section compares Cambium Bio Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $9,810,720
Average return on equity (ROE) among peers: -71.07%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Cambium Bio Ltd (CMB)	AU$1.84 Million	11.78%	0.79x	$6.66 Million
Adalta Ltd (1AD)	$3.70 Million	-162.25%	0.87x	$6.50 Million
Algorae Pharmaceuticals Ltd (1AI)	$-1.33 Million	0.00%	0.00x	$20.04 Million
ACRUX Ltd (ACR)	$12.85 Million	-73.71%	0.44x	$3.20 Million
Actinogen Medical Ltd (ACW)	$21.74 Million	-43.69%	0.07x	$105.70 Million
Argenica Therapeutics Ltd (AGN)	$13.95 Million	-39.28%	0.17x	$15.45 Million
Arovella Therapeutics Ltd (ALA)	$11.03 Million	-40.87%	0.23x	$58.08 Million
Anatara Lifesciences Ltd (ANR)	$924.54K	-218.83%	0.54x	$1.57 Million
Alterity Therapeutics Ltd (ATH)	$20.73 Million	-6.40%	0.01x	$76.95 Million
Amplia Therapeutics Ltd (ATX)	$11.23 Million	-30.16%	0.02x	$50.82 Million
Avecho Biotechnology Ltd (AVE)	$3.27 Million	-95.48%	0.53x	$28.59 Million

About Cambium Bio Ltd

AU:CMB Australia Biotechnology

Market Cap

$6.66 Million

AU$9.42 Million AUD

Market Cap Rank

#27781 Global

#1472 in Australia

Share Price

AU$0.41

Change (1 day)

-2.38%

52-Week Range

AU$0.19 - AU$0.60

All Time High

AU$22.97